Dr. Reddy's Laboratories Limited has informed the Exchange about General Updates
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The USFDA carried out a GMP and Pre-Approval Inspection (PAI) at Dr. Reddy's formulations manufacturing facility FTO 11 in Srikakulam, Andhra Pradesh, from July 10 to July 18, 2025. At the end of the inspection, the USFDA issued a Form 483 with 7 observations. The company has stated it will address the observations within the stipulated timeline. FTO 11 is a key formulations plant that supplies the US market, making the outcome relevant for ongoing and future product approvals from that site.
A Form 483 with multiple observations can delay future product approvals from the Srikakulam facility and may lead to short-term negative sentiment on the stock, though 7 observations is a moderate outcome and the company is responding within the required timeframe.